Should Urogenital Atrophy in Breast Cancer Survivors Be Treated With Topical Estrogens?

CME Activity Information
Release Date:	April 7, 2008
Most Recent Review:	April 7, 2008*
Most Recent Update:	April 7, 2008
Date Credit Expires:	April 7, 2010
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by April 7, 2010, in order to receive the credit or participation certificate.

1. Describe the urogenital consequences of antiestrogen treatment among women with a prior diagnosis of breast cancer and the effects that these side effects have on quality of life and medication compliance.
2. Advise on the standard treatment of urogenital atrophy, including alternatives to topical estrogen replacement, in the non–breast cancer and breast cancer populations.
3. Evaluate the evidence for the current recommendations of estrogen replacement therapy among women with a prior diagnosis of breast cancer.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://cme.theoncologist.com/misc/edboard.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All activity planners, authors, and reviewers are required to submit conflict of interest forms. These forms accompany the activity through the peer review process. Any reviewers who have a conflict of interest are recused. When a reviewer is recused, other suitable reviewers with no self-reported conflicts of interests are selected to conduct the reviews. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Medical Oncology Resident, Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Canada.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternatives uses of Replens^® (Wellspring Pharmaceutical) as a vaginal lubricant/moisturizer and Estring^® (Pfizer) and Vagifem^® (Novo Nordisk) as topical estrogen replacements. The author has indicated no relevant commercial relationships.

Sheray Chin, M.D.

Credentials: Medical Oncology Resident, Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Canada.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternatives uses of Replens^® (Wellspring Pharmaceutical) as a vaginal lubricant/moisturizer and Estring^® (Pfizer) and Vagifem^® (Novo Nordisk) as topical estrogen replacements. The author has indicated no relevant commercial relationships.

Wendy Wolfman, M.D., F.R.C.S.(C), F.A.C.O.G.

Credentials: Co-Director, Menopause Unit, Department of Obstetrics and Gynaecology, Mount Sinai Hospital, Toronto, Canada; Assistant Professor, University of Toronto, Toronto, Canada.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternatives uses of Replens^® (Wellspring Pharmaceutical) as a vaginal lubricant/moisturizer and Estring^® (Pfizer) and Vagifem^® (Novo Nordisk) as topical estrogen replacements. The author has received an honorarium from Wyeth and Berlex as a guest speaker at CME events.

Christine Simmons, M.D. F.R.C.P.(C)

Credentials: Clinical Fellow, Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Canada.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternatives uses of Replens^® (Wellspring Pharmaceutical) as a vaginal lubricant/moisturizer and Estring^® (Pfizer) and Vagifem^® (Novo Nordisk) as topical estrogen replacements. The author has indicated no relevant commercial relationships.

Mark Clemons, M.B.B.S., M.D., F.R.C.P.

Credentials: Head, Breast Oncology, Department of Hematology and Medical Oncology, Princess Margaret Hospital, Toronto, Canada; Assistant Professor, University of Toronto, Toronto, Canada.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternatives uses of Replens^® (Wellspring Pharmaceutical) as a vaginal lubricant/moisturizer and Estring^® (Pfizer) and Vagifem^® (Novo Nordisk) as topical estrogen replacements. The author has indicated no relevant commercial relationships.